Michael E. Doyle
Architects at 6 St, Boulder, CO
License number
Colorado 202059
Issued Date
Oct 1, 1984
Renew Date
Nov 1, 2015
Expiration Date
Oct 31, 2017
Type
Architect
Address
Address
997 6Th St, Boulder, CO 80302
Personal information
See more information about Michael E. Doyle at radaris.comName
Address
Phone
4695 Belford Cir, Broomfield, CO 80023
468 Stellars Jay Dr, Littleton, CO 80129
462 Tiara Dr, Grand Junction, CO 81507
Professional information
Reduced Side-Effect Hemoglobin Compositions
US Patent:
6670323, Dec 30, 2003
Filed:
Nov 10, 2000
Appl. No.:
09/709914
Inventors:
Douglas L. Looker - Lafayette CO
Izydor Z. Apostol - Boulder CO
Eric A. Brucker - Evergreen CO
Michael P. Doyle - Boulder CO
David L. Foster - Lafayette CO
Christopher B. Glascock - Louisville CO
James C. Hartman - Boulder CO
Geoffrey F. Lee - Boulder CO
Douglas D. Lemon - Louisville CO
Edwin G. Moore - Boulder CO
Jane P. Richards - Longmont CO
Michael R. Schick - Louisville CO
Stephen P. Trimble - Boulder CO
David Pereira - Apex NC
Ton-That Hai - Mundelein IL
Kenneth E. Burhop - Longmont CO
Izydor Z. Apostol - Boulder CO
Eric A. Brucker - Evergreen CO
Michael P. Doyle - Boulder CO
David L. Foster - Lafayette CO
Christopher B. Glascock - Louisville CO
James C. Hartman - Boulder CO
Geoffrey F. Lee - Boulder CO
Douglas D. Lemon - Louisville CO
Edwin G. Moore - Boulder CO
Jane P. Richards - Longmont CO
Michael R. Schick - Louisville CO
Stephen P. Trimble - Boulder CO
David Pereira - Apex NC
Ton-That Hai - Mundelein IL
Kenneth E. Burhop - Longmont CO
Assignee:
Baxter International, Inc. - Deerfield IL
Baxter Healthcare S.A. - Kanton Zurich
Baxter Healthcare S.A. - Kanton Zurich
International Classification:
C07K 14805
US Classification:
514 6, 535385
Abstract:
The invention relates to novel hemoglobin compositions, particularly novel recombinant mutant hemoglobin compositions, which eliminate or substantially reduce 1) the creation of heart lesions, 2) gastrointestinal discomfort, 3) pressor effects, and 4) endotoxin hypersensitivity associated with the administration of extracellular hemoglobin compositions in various therapeutic applications. Applications described include treatments for anemia, head injury, hemorrhage or hypovolemia, ischemia, cachexia, sickle cell crisis and stroke; enhancing cancer treatments; stimulating hematopoiesis; improving repair of physically damaged tissues; alleviating cardiogenic shock; and shock resuscitation.
Reduced Side-Effect Hemoglobin Compositions
US Patent:
7211560, May 1, 2007
Filed:
Dec 29, 2003
Appl. No.:
10/747580
Inventors:
Douglas L. Looker - Fort Lupton CO, US
Izydor Z. Apostol - Boulder CO, US
Eric A. Brucker - Evergreen CO, US
Michael P. Doyle - Boulder CO, US
David L. Foster - Lafayette CO, US
Christopher B. Glascock - Louisville CO, US
James C. Hartman - Boulder CO, US
Geoffrey F. Lee - Boulder CO, US
Douglas D. Lemon - Louisville CO, US
Edwin G. Moore - Boulder CO, US
Jane P. Richards - Longmont CO, US
Michael R. Schick - Louisville CO, US
Stephen P. Trimble - Boulder CO, US
David Pereira - Apex NC, US
Ton-That Hai - Mundelein IL, US
Kenneth E. Burhop - Longmont CO, US
Izydor Z. Apostol - Boulder CO, US
Eric A. Brucker - Evergreen CO, US
Michael P. Doyle - Boulder CO, US
David L. Foster - Lafayette CO, US
Christopher B. Glascock - Louisville CO, US
James C. Hartman - Boulder CO, US
Geoffrey F. Lee - Boulder CO, US
Douglas D. Lemon - Louisville CO, US
Edwin G. Moore - Boulder CO, US
Jane P. Richards - Longmont CO, US
Michael R. Schick - Louisville CO, US
Stephen P. Trimble - Boulder CO, US
David Pereira - Apex NC, US
Ton-That Hai - Mundelein IL, US
Kenneth E. Burhop - Longmont CO, US
Assignee:
Baxter International, Inc. - Deerfield IL
Baxter Healthcare S.A. - Zurich
Baxter Healthcare S.A. - Zurich
International Classification:
A61K 35/14
US Classification:
514 6, 530385
Abstract:
The invention relates to novel hemoglobin compositions, particularly novel recombinant mutant hemoglobin compositions, which eliminate or substantially reduce 1) the creation of heart lesions, 2) gastrointestinal discomfort, 3) pressor effects, and 4) endotoxin hypersensitivity associated with the administration of extracellular hemoglobin compositions in various therapeutic applications. Applications described include treatments for anemia, head injury, hemorrhage or hypovolemia, ischemia, cachexia, sickle cell crisis and stroke; enhancing cancer treatments; stimulating hematopoiesis; improving repair of physically damaged tissues; alleviating cardiogenic shock; and shock resuscitation.